Published in Hepatology on April 01, 2010
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One (2012) 1.05
An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol (2010) 1.00
Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome. Rev Diabet Stud (2012) 0.99
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98
Management of hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.96
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol (2015) 0.96
Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant (2014) 0.94
Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol (2014) 0.94
Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. Cancer Med (2013) 0.91
Autophagy and non-alcoholic fatty liver disease. Biomed Res Int (2014) 0.87
Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation. World J Surg (2012) 0.87
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86
Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci (2013) 0.85
Autophagy: A novel therapeutic target for hepatocarcinoma (Review). Oncol Lett (2014) 0.84
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol (2011) 0.84
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol (2013) 0.83
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol (2016) 0.83
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82
Liver Transplantation for HCC: A Review. Indian J Surg (2011) 0.82
The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol (2011) 0.82
Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol (2015) 0.81
Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol (2015) 0.81
Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81
Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transpl Int (2011) 0.81
Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One (2011) 0.80
Autophagy: a primer for the gastroenterologist/hepatologist. Can J Gastroenterol (2011) 0.80
Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol (2015) 0.80
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbecks Arch Surg (2013) 0.79
Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann Gastroenterol (2015) 0.79
Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence. World J Gastroenterol (2011) 0.79
Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database. PLoS One (2016) 0.78
Inhibition of mammalian target of rapamycin: two goals with one shot? J Hepatol (2010) 0.78
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol (2017) 0.78
Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma. Hepatology (2010) 0.77
The Role of Autophagy in Hepatocellular Carcinoma. Int J Mol Sci (2015) 0.77
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol (2015) 0.77
Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg (2014) 0.77
Inhibition of mammalian target of rapamycin: the janus face of immunosuppression? Hepatology (2010) 0.77
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget (2015) 0.77
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World J Gastroenterol (2016) 0.76
Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant (2014) 0.76
Rapamycin enhances HBV production by inducing cellular autophagy. Hepat Mon (2014) 0.76
Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol (2014) 0.76
A Decade of Experience Using mTor Inhibitors in Liver Transplantation. J Transplant (2011) 0.76
Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl (2016) 0.76
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75
Hepatocellular carcinoma following renal transplantation. Gastrointest Cancer Res (2011) 0.75
Blood Transfusions and Tumor Biopsy May Increase HCC Recurrence Rates after Liver Transplantation. J Transplant (2017) 0.75
Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol (2016) 0.75
Use of Everolimus in Liver Transplantation: Recommendations From a Working Group. Transplantation (2017) 0.75
Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. PLoS One (2016) 0.75
Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. Transl Gastroenterol Hepatol (2016) 0.75
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol (2016) 0.75
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. Hepat Med (2011) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection? Transl Gastroenterol Hepatol (2017) 0.75
Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Gastric adenocarcinoma: review and considerations for future directions. Ann Surg (2005) 3.83
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 2.36
Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes (2009) 2.31
Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes (2004) 2.22
Cell encapsulation: promise and progress. Nat Med (2003) 2.18
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol (2011) 2.12
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Islet graft assessment in the Edmonton Protocol: implications for predicting long-term clinical outcome. Diabetes (2004) 1.98
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant (2007) 1.78
Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines. PLoS One (2012) 1.76
Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A (2009) 1.72
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes (2002) 1.61
Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int (2009) 1.58
Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl (2010) 1.57
BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol (2009) 1.53
Cardiopulmonary resuscitation with chest compressions during sustained inflations: a new technique of neonatal resuscitation that improves recovery and survival in a neonatal porcine model. Circulation (2013) 1.51
Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes (2004) 1.46
Edmonton's islet success has indeed been replicated elsewhere. Lancet (2003) 1.45
Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device. Transplantation (2015) 1.44
Postresuscitation administration of doxycycline preserves cardiac contractile function in hypoxia-reoxygenation injury of newborn piglets*. Crit Care Med (2014) 1.40
Update on islet transplantation. Cold Spring Harb Perspect Med (2012) 1.40
Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care (2005) 1.35
Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology (2003) 1.34
Strategic opportunities in clinical islet transplantation. Transplantation (2005) 1.34
Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes (2002) 1.32
Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res (2007) 1.31
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant (2007) 1.27
Current status of clinical islet cell transplantation. Methods Mol Biol (2006) 1.25
Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers. Int J Parasitol (2006) 1.24
Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant (2005) 1.23
Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes (2006) 1.21
Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation (2004) 1.17
TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res (2004) 1.15
Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant (2007) 1.14
The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit (2005) 1.14
Estimation of pancreas weight from donor variables. Cell Transplant (2006) 1.13
Islet isolation and transplantation outcomes of pancreas preserved with University of Wisconsin solution versus two-layer method using preoxygenated perfluorocarbon. Transplantation (2006) 1.12
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes (2005) 1.12
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Current status of pancreatic islet transplantation. Clin Sci (Lond) (2006) 1.11
Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic β-cells through glycolysis and calcium channels. Endocrinology (2011) 1.11
Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation (2010) 1.10
Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog (2006) 1.09
Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab (2006) 1.08
A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology (2012) 1.08
Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther (2006) 1.08
m-TOR inhibitors: what role in liver transplantation? J Hepatol (2011) 1.06
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation (2010) 1.06
Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes (2006) 1.05
Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin Dev Immunol (2013) 1.04
Factors influencing the collagenase digestion phase of human islet isolation. Transplantation (2007) 1.03
Surgical aspects of human islet isolation. Islets (2010) 1.03
Circumportal pancreas and islet isolation. Surgery (2008) 1.03
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs (2004) 1.01
An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol (2010) 1.00
Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal (2007) 1.00
Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant (2004) 1.00
Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int (2008) 1.00
Risks and side effects of islet transplantation. Curr Diab Rep (2004) 1.00
Beta-cell transplantation for diabetes therapy. Lancet (2008) 0.99
IFN-gamma is an absolute requirement for spontaneous acceptance of liver allografts. Am J Transplant (2003) 0.99
Application of the trak-C HCV core assay for monitoring antiviral activity in HCV replication systems. J Virol Methods (2004) 0.98
Current indications for pancreas or islet transplant. Diabetes Obes Metab (2006) 0.98
Technical aspects of islet preparation and transplantation. Transpl Int (2003) 0.98
Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation (2007) 0.98
Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol (2002) 0.98
Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes (2007) 0.97
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Role of imaging in clinical islet transplantation. Radiographics (2010) 0.95
The place of downstaging for hepatocellular carcinoma. J Hepatol (2010) 0.95
Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras. J Immunol (2008) 0.95
Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management. Liver Transpl (2010) 0.95
Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology (2009) 0.95
The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes (2008) 0.95